-
FDA Announces New Digital Drug Package Inserts / Labels Project
Drug Companies To Submit Digital Versions For All Drugs In Coming Year On November 2, 2005 the FDA announced a new project which will involve drug companies submitting digital versions of drug package inserts,…
-
Wyeth Wins Latest Three Fen-Phen Diet-Drug Cases
Several Hundred Fen-Phen Cases Still Pending and Headed to Trial On October 31, 2005 the drug company Wyeth announced that it had won the latest three fen-phen diet-drug cases: Lee Ann Brunson v. Wyeth;…
-
Biogen and FDA Warn of Severe Skin Reactions To Lymphoma Drug Zevalin
Toxic Epidermal Necrolysis (TEN), Stevens-Johnson Syndrome (SJS), and Erythema Multiforme (EM) In late October 2005 Biogen Idec Inc. and the FDA warned doctors about severe and sometimes fatal skin reactions that have been reported…
-
New Jersey / NJ Vioxx Trial: Humeston Case Goes to Jury After Closing Arguments
Humeston v. Merck Verdict: Will The Jury Weigh In For The Plaintiff or Defense? Today, after a seven-week trial, a New Jersey state court jury in the Humeston v. Merck Vioxx case should hear…
-
FDA Probably Will Not Require Longer Studies Of New Psychiatric Drugs
Advisory Panel Rejects FDA Proposal: Good Idea, But Wrong Approach In late October 2005 an FDA advisory panel rejected the agency’s recent proposal that would have required the drug companies to do longer-term studies…
-
“Off-label” Prescribing of Psychosis Drugs For Alzheimer’s Has Risks
Careful Consideration Needed When Prescribing Zyprexa or Risperdal for Alzheimer’s-related Dementia Elderly patients with Alzheimer’s disease who are prescribed antipsychotic drugs such as Zyprexa and Risperdal have a higher risk of dying than patients…
